FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2047650149> ?p ?o ?g. }

• W2047650149 endingPage "1792" @default.
• W2047650149 startingPage "1783" @default.
• W2047650149 abstract "Multiple myeloma is an incurable plasma cell neoplasia characterized by the production of large amounts of monoclonal immunoglobulins. The proteasome inhibitor bortezomib (PS-341, Velcade) induces apoptosis in various malignant cells and has been approved for treatment of refractory multiple myeloma. Inhibition of the antiapoptotic transcription factor nuclear factor-kappaB (NF-kappaB) apparently contributes to the antitumor effects of bortezomib; however, this mechanism cannot fully explain the exceptional sensitivity of myeloma cells. Extensive protein synthesis as in myeloma cells is inherently accompanied by unfolded proteins, including defective ribosomal products (DRiPs), which need to be degraded by the ubiquitin-proteasome system. Therefore, we hypothesized that the proapoptotic effect of bortezomib in multiple myeloma is mainly due to the accumulation of unfolded proteins in cells with high protein biosynthesis. Using the IgG-secreting human myeloma cell line JK-6L and murine muH-chain-transfected Ag8.H myeloma cells, apoptosis induction upon proteasome inhibition was clearly correlated with the amount of immunoglobulin production. Preferentially in immunoglobulin-high myeloma cells, bortezomib triggered activation of caspases and induction of proapoptotic CHOP, a component of the terminal unfolded protein response induced by endoplasmic reticulum (ER) stress. In immunoglobulin-high cells, bortezomib increased the levels of proapoptotic Bax while reducing antiapoptotic Bcl-2. Finally, IgG-DRiPs were detected in proteasome inhibitor-treated cells. Hence, proteasome inhibitors induce apoptosis preferentially in cells with high synthesis rate of immunoglobulin associated with accumulation of unfolded proteins/DRiPs inducing ER stress. These findings further elucidate the antitumor activities of proteasome inhibitors and have important implications for optimizing clinical applications." @default.
• W2047650149 created "2016-06-24" @default.
• W2047650149 creator A5004962774 @default.
• W2047650149 creator A5006887013 @default.
• W2047650149 creator A5010585822 @default.
• W2047650149 creator A5021048477 @default.
• W2047650149 creator A5039333578 @default.
• W2047650149 creator A5048548826 @default.
• W2047650149 creator A5060234158 @default.
• W2047650149 creator A5060482398 @default.
• W2047650149 creator A5061020169 @default.
• W2047650149 creator A5064893843 @default.
• W2047650149 creator A5075012306 @default.
• W2047650149 creator A5080484559 @default.
• W2047650149 date "2007-02-15" @default.
• W2047650149 modified "2023-10-18" @default.
• W2047650149 title "Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition" @default.
• W2047650149 cites W1759028523 @default.
• W2047650149 cites W1782287000 @default.
• W2047650149 cites W1915442041 @default.
• W2047650149 cites W1925735392 @default.
• W2047650149 cites W1967059605 @default.
• W2047650149 cites W1967578320 @default.
• W2047650149 cites W1970090817 @default.
• W2047650149 cites W1976601347 @default.
• W2047650149 cites W1977498240 @default.
• W2047650149 cites W1978188507 @default.
• W2047650149 cites W1991958238 @default.
• W2047650149 cites W2001991475 @default.
• W2047650149 cites W2010250072 @default.
• W2047650149 cites W2010494349 @default.
• W2047650149 cites W2010668098 @default.
• W2047650149 cites W2012324563 @default.
• W2047650149 cites W2024846074 @default.
• W2047650149 cites W2025846979 @default.
• W2047650149 cites W2026642838 @default.
• W2047650149 cites W2029642537 @default.
• W2047650149 cites W2046242381 @default.
• W2047650149 cites W2051831012 @default.
• W2047650149 cites W2064776807 @default.
• W2047650149 cites W2067653691 @default.
• W2047650149 cites W2069924169 @default.
• W2047650149 cites W2072714194 @default.
• W2047650149 cites W2077754831 @default.
• W2047650149 cites W2080901528 @default.
• W2047650149 cites W2084925682 @default.
• W2047650149 cites W2094202570 @default.
• W2047650149 cites W2100347985 @default.
• W2047650149 cites W2107601804 @default.
• W2047650149 cites W2113915760 @default.
• W2047650149 cites W2115137627 @default.
• W2047650149 cites W2117707319 @default.
• W2047650149 cites W2119689749 @default.
• W2047650149 cites W2127684300 @default.
• W2047650149 cites W2128056949 @default.
• W2047650149 cites W2128786825 @default.
• W2047650149 cites W2129515878 @default.
• W2047650149 cites W2131595439 @default.
• W2047650149 cites W2132485651 @default.
• W2047650149 cites W2133425838 @default.
• W2047650149 cites W2136735139 @default.
• W2047650149 cites W2137755719 @default.
• W2047650149 cites W2143952529 @default.
• W2047650149 cites W2148119611 @default.
• W2047650149 cites W2149843709 @default.
• W2047650149 cites W2151438792 @default.
• W2047650149 cites W2169295136 @default.
• W2047650149 cites W2466683697 @default.
• W2047650149 cites W4246021513 @default.
• W2047650149 doi "https://doi.org/10.1158/0008-5472.can-06-2258" @default.
• W2047650149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17308121" @default.
• W2047650149 hasPublicationYear "2007" @default.
• W2047650149 type Work @default.
• W2047650149 sameAs 2047650149 @default.
• W2047650149 citedByCount "366" @default.
• W2047650149 countsByYear W20476501492012 @default.
• W2047650149 countsByYear W20476501492013 @default.
• W2047650149 countsByYear W20476501492014 @default.
• W2047650149 countsByYear W20476501492015 @default.
• W2047650149 countsByYear W20476501492016 @default.
• W2047650149 countsByYear W20476501492017 @default.
• W2047650149 countsByYear W20476501492018 @default.
• W2047650149 countsByYear W20476501492019 @default.
• W2047650149 countsByYear W20476501492020 @default.
• W2047650149 countsByYear W20476501492021 @default.
• W2047650149 countsByYear W20476501492022 @default.
• W2047650149 countsByYear W20476501492023 @default.
• W2047650149 crossrefType "journal-article" @default.
• W2047650149 hasAuthorship W2047650149A5004962774 @default.
• W2047650149 hasAuthorship W2047650149A5006887013 @default.
• W2047650149 hasAuthorship W2047650149A5010585822 @default.
• W2047650149 hasAuthorship W2047650149A5021048477 @default.
• W2047650149 hasAuthorship W2047650149A5039333578 @default.
• W2047650149 hasAuthorship W2047650149A5048548826 @default.
• W2047650149 hasAuthorship W2047650149A5060234158 @default.
• W2047650149 hasAuthorship W2047650149A5060482398 @default.
• W2047650149 hasAuthorship W2047650149A5061020169 @default.
• W2047650149 hasAuthorship W2047650149A5064893843 @default.

• next